BCI
CSTL icon

Brinker Capital Investments’s Castle Biosciences CSTL Stock Holding History

Brinker Capital Investments’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.66M Sell
69,654
-5,242
-7% -$117K 0.01% 900
2026
Q1 		$1.84M Buy
74,896
+243
+0.3% +$7.96K 0.02% 793
2025
Q4 		$2.9M Sell
74,653
-1,691
-2% -$54.5K 0.02% 661
2025
Q3 		$1.74M Sell
76,344
-188
-0.2% -$3.82K 0.01% 914
2025
Q2 		$1.56M Sell
76,532
-1,877
-2% -$34.7K 0.01% 931
2025
Q1 		$1.57M Buy
78,409
+10,093
+15% +$250K 0.02% 836
2024
Q4 		$1.82M Sell
68,316
-4,089
-6% -$125K 0.02% 751
2024
Q3 		$2.06M Buy
72,405
+10,324
+17% +$263K 0.02% 673
2024
Q2 		$1.35M Sell
62,081
-5,156
-8% -$115K 0.01% 836
2024
Q1 		$1.49M Sell
67,237
-2,496
-4% -$54.3K 0.02% 798
2023
Q4 		$1.53M Sell
69,733
-4,294
-6% -$75.6K 0.02% 759
2023
Q3 		$1.25M Sell
74,027
-3,523
-5% -$61.6K 0.02% 824
2023
Q2 		$1.06M Buy
77,550
+47,885
+161% +$970K 0.01% 927
2023
Q1 		$674K Sell
29,665
-3,159
-10% -$77.2K 0.01% 1031
2022
Q4 		$773K Sell
32,824
-3,636
-10% -$84.3K 0.02% 824
2022
Q3 		$951K Buy
36,460
+7,882
+28% +$221K 0.02% 731
2022
Q2 		$627K Sell
28,578
-6,683
-19% -$155K 0.01% 896
2022
Q1 		$1.58M Buy
35,261
+7,541
+27% +$312K 0.02% 623
2021
Q4 		$1.19M Sell
27,720
-22,441
-45% -$1.17M 0.02% 751
2021
Q3 		$3.68M Hold
50,161
– – 0.06% 347
2021
Q2 		$3.68M Buy
+50,161
New +$3.31M 0.05% 396

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Brinker Capital Investments's CSTL Position: Q2 2026 in Review

Brinker Capital Investments reduced its Castle Biosciences (CSTL) stake by 7% in Q2 2026, selling an estimated $117K and leaving 69,654 shares worth $1.66M. The position accounts for 0.01% of the portfolio, ranked #900.

Brinker Capital Investments first reported a position in CSTL in Q2 2021 and has held it in 21 quarters since. The position peaked at $3.68M in Q3 2021. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Brinker Capital Investments held 69,654 shares of Castle Biosciences worth $1.66M as of Q2 2026.
  • Brinker Capital Investments sold 5,242 Castle Biosciences shares in Q2 2026, an estimated $117K.
  • Castle Biosciences made up 0.01% of Brinker Capital Investments's portfolio in Q2 2026, its #900 holding.
  • Brinker Capital Investments first reported a position in Castle Biosciences in Q2 2021 and has held it in 21 quarters since.
  • Brinker Capital Investments's Castle Biosciences position peaked at $3.68M in Q3 2021.
  • 177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Brinker Capital Investments's 13F filing for Q2 2026, filed 14 Aug 2026.